Novel Advances in Obesity Management and Therapeutics

To participate in this activity, please:

This live event is held at the Annenberg Health Sciences Building on the Eisenhower Health Campus.

Course Credit:

1.00 AMA PRA Category 1 CreditTM
1.00 CA-BRN Contact Hour

Dates:

Opens: 2026-05-14
Closes: 2026-06-14

Target Audience:

This activity was developed for physicians including Eisenhower medical staff along with nurses and ancillary staff.

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Kurt Hong, MD, PhD, FACN  headshot

    Kurt Hong, MD, PhD, FACN

    Professor of Clinical Medicine USC Keck School of Medicine
    Davis School of Gerontology
    Founding Director, Center for Clinical Nutrition
    University of Southern California
    Los Angeles, California

Downloads

This course has no downloads at this time.

Learning Objectives

  • Characterize the mechanistic landscape of emerging pharmacologic agents, including GLP-1 receptor agonists and dual GIP/GLP-1 agonists
  • Evaluate clinical efficacy and safety data from pivotal trials (SURMOUNT, STEP, OASIS, and ACCESS series), including comparisons of weight loss outcomes
  • Apply a framework for therapeutic selection by matching anti-obesity agents to patient phenotype, comorbidity burden, and treatment goals

Faculty Disclosures

Kurt Hong, MD, PhD, FACN

No relationships to disclose.